Core Viewpoint - The internal audit system of Jiangxi Tianxin Pharmaceutical Co., Ltd. is established to enhance internal supervision and risk control, ensuring compliance with laws and regulations while protecting investors' rights [3]. Group 1: General Principles - The internal audit aims to supervise and evaluate the authenticity, legality, and effectiveness of financial expenditures, asset quality, operational performance, and construction projects of the company and its subsidiaries [3]. - This internal audit system applies to the company and its wholly-owned and controlling subsidiaries [3]. Group 2: Audit Organization and Personnel - An audit department is established under the board's audit committee to independently conduct audit work and report directly to the audit committee [4][5]. - The audit department must maintain independence and is not to be under the leadership of the finance department [5]. - Audit personnel are required to be professional, objective, and maintain confidentiality, with a duty to avoid conflicts of interest [6][7]. Group 3: Audit Responsibilities - The audit department is responsible for supervising the company's operational activities, financial expenditures, economic benefits, and the performance of senior management [8]. - The audit work aims to improve management and enhance economic efficiency while ensuring the integrity and safety of the company's assets [9][10]. Group 4: Audit Authority and Scope - The audit department has the authority to inspect all relevant management accounts and documents during the audit period [13]. - The audit department is tasked with establishing a fraud prevention mechanism and reporting any significant issues to the audit committee [8][12]. Group 5: Audit Procedures - The audit department must prepare an audit plan and obtain approval from the audit committee before implementation [23]. - Audit reports must be objective, complete, and timely, reflecting the findings and suggestions based on verified evidence [24][25]. Group 6: Rewards and Penalties - Departments and individuals achieving significant results in implementing the internal audit system will be recognized or rewarded [28]. - Violations of the internal audit system may lead to administrative penalties or criminal charges depending on the severity of the actions [30][31].

Core Points - Jiangxi Tianxin Pharmaceutical Co., Ltd. was established as a joint-stock company through the overall transformation of Jiangxi Tianxin Pharmaceutical Co., Ltd. [1] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue 43.78 million shares of ordinary stock to the public on June 13, 2022, and was listed on the Shanghai Stock Exchange on July 12, 2022 [1] - The registered capital of the company is RMB 437.78 million, and it is located in the industrial park of Lepin City, Jingdezhen, Jiangxi Province [1] Company Structure - The company is governed by its articles of association, which are legally binding for the company, shareholders, directors, and senior management [1] - The legal representative of the company is the chairman or general manager, who must be appointed within 30 days of resignation [1] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [1] Business Objectives and Scope - The company's business objectives include strengthening the enterprise, achieving employee success, serving society, and promoting human health [1] - The business scope includes drug production, drug wholesale, production of feed additives, food additives, and hazardous chemicals, among others [1] Share Issuance and Management - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice [3] - The company has issued a total of 43.78 million shares, all of which are ordinary shares with a par value of RMB 1 per share [4] - The company may increase or decrease its registered capital based on shareholder resolutions and legal regulations [3][4] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, supervision of company operations, and access to company documents [7] - Shareholders must comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [9] - The company must maintain a shareholder register based on records from the securities registration and settlement institution [7] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [10] - Shareholder meetings can be convened by the board of directors or at the request of shareholders holding more than 10% of the shares [10] - Decisions made at shareholder meetings require a majority or two-thirds majority vote, depending on the type of resolution [18]

Core Insights - Tianxin Pharmaceutical (603235.SH) reported a total revenue of 1.122 billion yuan and a net profit attributable to shareholders of 356 million yuan for the first half of 2025 [1] - The company experienced a net cash inflow from operating activities of 342 million yuan [1] Financial Performance - The latest debt-to-asset ratio is 18.66%, which is an increase of 1.84 percentage points from the previous quarter and an increase of 3.48 percentage points year-on-year [3] - The latest gross profit margin stands at 47.83%, reflecting a decrease of 2.00 percentage points from the previous quarter [3] - The return on equity (ROE) is 7.61%, down by 0.37 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.82 yuan [3] Efficiency Metrics - The total asset turnover ratio is 0.20 times, ranking 114th among disclosed peers, which is a decrease of 0.01 times year-on-year, representing a decline of 5.59% [3] - The inventory turnover ratio is 0.98 times, ranking 150th among disclosed peers, with a decrease of 0.31 times year-on-year, indicating a decline of 24.09% [3] Shareholder Structure - The number of shareholders is 14,800, with the top ten shareholders holding a total of 398 million shares, accounting for 90.97% of the total share capital [3] - The largest shareholder is Xu Jiangnan, holding 46.5% of the shares [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 第二节 公司基本情况 2.1公司简介 ■ 公司代码：603235 公司简称：天新药业 第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到http://www.sse.com.cn/网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对 ...

（文章来源：证券日报） 证券日报网讯 8月28日晚间，天新药业发布公告称，公司第三届董事会第十一次会议审议通过了《关于 提请召开2025年第一次临时股东大会的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月28日晚间，天新药业发布公告称，公司第三届监事会第十次会议审议通过了《关于公 司2025年半年度报告及其摘要的议案》等。 ...

证券代码：603235 证券简称：天新药业 公告编号：2025-035 江西天新药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025年第一次临时股东大会 召开的日期时间：2025 年 9 月 17 日 14 点 30 分 召开地点：江西省景德镇市乐平市工业园工业六路江西天新药业股份有限公 司会议室 股东大会召开日期：2025年9月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 17 日 至2025 年 9 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票 ...

证券代码：603235 证券简称：天新药业 公告编号：2025-030 江西天新药业股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、监事会会议审议情况 （一） 审议通过《关于公司 2025 年半年度报告及其摘要的议案》 监事会认为： （1）公司《2025 年半年度报告》及摘要的编制和审议程序符合《公开发行 证券的公司信息披露内容与格式准则第 3 号——半年度报告的内容与格式（2025 年修订）》《江西天新药业股份有限公司章程》等相关法律法规的有关规定； （2）公司《2025 年半年度报告》及摘要真实地反映了公司报告期内的财务 状况和经营成果； （3）公司《2025 年半年度报告》及摘要所披露的信息真实、准确、完整， 承诺其中不存在虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确 性和完整性承担个别和连带的法律责任； （4）公司《2025 年半年度报告》及摘要编制过程中，未发现公司参与年度 报告编制和审议的人员有违反保密规定的行为。 该议案同意票数为 3 票，反对票数为 ...

江西天新药业股份有限公司 第三届董事会第十一次会议决议公告 证券代码：603235 证券简称：天新药业 公告编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一） 审议通过《关于公司 2025 年半年度报告及其摘要的议案》； 该议案同意票数为 8 票，反对票数为 0 票，弃权票数为 0 票。该议案已 经董事会审计委员会审议通过。 具体内容详见公司同日刊登在上海证券交易所（www.sse.com.cn）上的 《2025 年半年度报告》及刊登在上海证券交易所（www.sse.com.cn）与公司 指定披露媒体上的《2025 年半年度报告摘要》。 （二） 审议通过《关于 2025 年半年度募集资金存放与使用情况的专项报告 的议案》； 该议案同意票数为 8 票，反对票数为 0 票，弃权票数为 0 票。 具体内容详见公司同日刊登在上海证券交易所（www.sse.com.cn）及公 司指定披露媒体上的《关于 2025 年半年度募集资金存放与使用情况的专项 报告的公告》（公告编号：2025-032）。 一、董事会会议 ...

格隆汇8月28日丨天新药业(603235.SH)公布2025年半年度报告，报告期内，公司实现营业收入11.22亿 元，同比增长5.23%；归属于上市公司股东的净利润3.56亿元，同比增长3.14%；归属于上市公司股东的 扣除非经常性损益的净利润3.36亿元，同比增长2.15%；基本每股收益0.82元。 ...